-
1.
Digital Health COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.
Lee, P, Abernethy, A, Shaywitz, D, Gundlapalli, AV, Weinstein, J, Doraiswamy, PM, Schulman, K, Madhavan, S
NAM perspectives. 2022
-
2.
The impact of COVID-19 on the pediatric solid organ transplant population.
Feldman, AG, Danziger-Isakov, LA
Seminars in pediatric surgery. 2022;(3):151178
-
-
Free full text
-
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly impacted all aspects of healthcare including solid organ transplantation. In this review, we discuss the specific impact of COVID-19 on the pediatric solid organ transplant population including access to grafts for pediatric transplant candidates as well as COVID-19 disease manifestations in pediatric transplant recipients. We address the current knowledge of prevention and management of COVID-19 in pediatric transplant recipients and provide additional information regarding social distancing, infection prevention and return to school.
-
3.
Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show?
Brahma, S, Naik, A, Lordan, R
Clinical nutrition ESPEN. 2022;:17-27
-
-
Free full text
-
Abstract
Since the global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), research has focused on understanding the etiology of coronavirus disease 2019 (COVID-19). Identifying and developing prophylactic and therapeutics strategies to manage the pandemic is still of critical importance. Among potential targets, the role of the gut and lung microbiomes in COVID-19 has been questioned. Consequently, probiotics were touted as potential prophylactics and therapeutics for COVID-19. In this review we highlight the role of the gut and lung microbiome in COVID-19 and potential mechanisms of action of probiotics. We also discuss the progress of ongoing clinical trials for COVID-19 that aim to modulate the microbiome using probiotics in an effort to develop prophylactic and therapeutic strategies. To date, despite the large interest in this area of research, there is promising but limited evidence to suggest that probiotics are an effective prophylactic or treatment strategy for COVID-19. However, the role of the microbiome in pathogenesis and as a potential target for therapeutics of COVID-19 cannot be discounted.
-
4.
Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D.
Torres, M, Casado, G, Vigón, L, Rodríguez-Mora, S, Mateos, E, Ramos-Martín, F, López-Wolf, D, Sanz-Moreno, J, Ryan-Murua, P, Taboada-Martínez, ML, et al
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022;:112965
-
-
Free full text
-
Abstract
Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/ml (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D3) for 14 days, in comparison with 2000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/ml on average in 2000 IU/day versus 29 ng/ml in 10,000 IU/day group (p < 0.0001). Although levels of inflammatory cytokines were not modified by treatment with 10,000 IU/day, there was an increase of anti-inflammatory cytokine IL-10 and higher levels of CD4+ T cells, with predominance of T central memory subpopulation. Cytotoxic response against pseudotyped SARS-CoV-2 infected cells was increased more than 4-fold in patients who received 10,000 IU/day. Moreover, levels of IFNγ were significantly higher in this group. Beneficial effect of supplementation with 10,000 IU/day was also observed in participants who developed ARDS and stayed at the hospital for 8.0 days, whereas those who received 2000 IU/day stayed for 29.2 days (p = 0.0381). Administration of high doses of vitamin D3 as adjuvant of the standard care treatment during hospitalization for COVID-19 may improve the inflammatory environment and cytotoxic response against pseudotyped SARS-CoV-2 infected cells, shortening the hospital stay and, possibly, improving the prognosis.
-
5.
Extracorporeal Membrane Oxygenation during Respiratory Pandemics: Past, Present, and Future.
Brodie, D, Abrams, D, MacLaren, G, Brown, CE, Evans, L, Barbaro, RP, Calfee, CS, Hough, CL, Fowles, JA, Karagiannidis, C, et al
American journal of respiratory and critical care medicine. 2022;(12):1382-1390
-
-
Free full text
-
Abstract
The role of extracorporeal membrane oxygenation (ECMO) in the management of severe acute respiratory failure, including acute respiratory distress syndrome, has become better defined in recent years in light of emerging high-quality evidence and technological advances. Use of ECMO has consequently increased throughout many parts of the world. The coronavirus disease (COVID-19) pandemic, however, has highlighted deficiencies in organizational capacity, research capability, knowledge sharing, and resource use. Although governments, medical societies, hospital systems, and clinicians were collectively unprepared for the scope of this pandemic, the use of ECMO, a highly resource-intensive and specialized form of life support, presented specific logistical and ethical challenges. As the pandemic has evolved, there has been greater collaboration in the use of ECMO across centers and regions, together with more robust data reporting through international registries and observational studies. Nevertheless, centralization of ECMO capacity is lacking in many regions of the world, and equitable use of ECMO resources remains uneven. There are no widely available mechanisms to conduct large-scale, rigorous clinical trials in real time. In this critical care review, we outline lessons learned during COVID-19 and prior respiratory pandemics in which ECMO was used, and we describe how we might apply these lessons going forward, both during the ongoing COVID-19 pandemic and in the future.
-
6.
Molecular modeling identification of potential drug candidates from selected African plants against SARS-CoV-2 key druggable proteins.
Uhomoibhi, JO, Idowu, KA, Shode, FO, Sabiu, S
Scientific African. 2022;:e01279
Abstract
Coronavirus disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is one of the major health threats the world has experienced. In order to stem the tide of the virus and its associated disease, rapid efforts have been dedicated to identifying credible anti-SARS-CoV-2 drugs. This study forms part of the continuing efforts to develop anti-SARS-CoV-2 molecules and employed a computational structure-activity relationship approach with emphasis on 99 plant secondary metabolites from eight selected African medicinal plants with proven therapeutic benefits against respiratory diseases focusing on the viral protein targets [Spike protein (Sgp), Main protease (Mpro), and RNA-dependent RNA polymerase (RdRp)]. The results of the molecular dynamics simulation of the best docked compounds presented as binding free energy revealed that three compounds each against the Sgp (VBS, COG and ABA), and Mpro (COR, QOR and ABG) had higher and better affinity for the proteins than the respective reference drugs, cefoperazone (CSP) and Nelfinavir (NEF), while four compounds (HDG, VBS, COR and KOR) had higher and favorable binding affinity towards RdRp than the reference standard, ramdesivir (RDS). Analysis of interaction with the receptor binding domain amino acid residues of Sgp showed that VBS had the highest number of interactions (17) relative to 14 and 13 for COG and ABA, respectively. For Mpro, COR showed interactions with catalytic dyad residues (His172 and Cys145). Compared to RDS, COR, HDG, VBS and KOR formed 19, 18, 17 and 12 H-bond and Van der Waal bonds, respectively, with RdRp. Furthermore, structural examination of the three proteins after binding to the lead compounds revealed that the compounds formed stable complexes. These observations suggest that the identified compounds might be beneficial in the fight against COVID-19 and are suggested for further in vitro and in vivo experimental validation.
-
7.
Disinfection of corona and myriad viruses in water by non-thermal plasma: a review.
Guesmi, A, Cherif, MM, Baaloudj, O, Kenfoud, H, Badawi, AK, Elfalleh, W, Hamadi, NB, Khezami, L, Assadi, AA
Environmental science and pollution research international. 2022;(37):55321-55335
-
-
Free full text
-
Abstract
Nowadays, in parallel to the appearance of the COVID-19 virus, the risk of viruses in water increases leading to the necessity of developing novel disinfection methods. This review focuses on the route of virus contamination in water and introduces non-thermal plasma technology as a promising method for the inactivation of viruses. Effects of essential parameters affecting the non-thermal discharge for viral inactivation have been exposed. The review has also illustrated a critical discussion of this technology with other advanced oxidation processes. Additionally, the inactivation mechanisms have also been detailed based on reactive oxygen and nitrogen species.
-
8.
COVID-19 Infection in Kidney Transplant Recipients: A Single Center Experience.
Akagun, T, Kavraz Tomar, O, Usta, M, Baylan, S
Transplantation proceedings. 2022;(6):1424-1428
-
-
Free full text
-
Abstract
BACKGROUND Kidney transplant recipients appear to be particularly high risk for critical COVID-19 illness owing to chronic immunosuppression and coexisting conditions. The aim of this study is to present the clinical characteristics and outcomes of our hospital's kidney transplant recipients who were hospitalized due to COVID-19 infection. METHODS In our retrospective observational study of COVID-19 PCR-positive patients, 31 of them were hospitalized with COVID-19 pneumonia and they were evaluated using demographics, laboratory data, treatment, and outcome. The prognostic nutritional index (PNI), which is calculated using the serum albumin concentration and total lymphocytic count, was also evaluated. The baseline immunosuppressive therapy of patients at the time of admission and the treatments they received during their hospitalization were recorded. All patients were treated with favipiravir. RESULTS Of the 31 renal transplant patients with COVID-19 pneumonia, 20 were male and the mean age was 52.7 ± 13.4. Nine (29%) of the patients died. All patients were treated with favipiravir for 5 days; laboratory tests were recorded before and after treatment. The mean PNI of the patients who survived was higher than the patients who died. CONCLUSIONS The 9 patients who died had lower PNI and higher neutrophil-to-lymphocyte ratio (NLR), creatinine, l-lactate dehydrogenase (LDH), ferritin, and C-reactive protein (CRP) levels. Hospitalized kidney transplant recipients with COVID-19 have higher rates of mortality. The PNI exhibited good predictive performance and may be a useful clinical marker that can be used for estimating survival in COVID-19 patients.
-
9.
Investigational drugs for the treatment of olfactory dysfunction.
Di Stadio, A, Severini, C, Colizza, A, De Vincentiis, M, La Mantia, I
Expert opinion on investigational drugs. 2022;(9):945-955
Abstract
INTRODUCTION Olfactory dysfunction could be the sign of acquired or degenerative diseases. The loss of the sense can be caused by a damage in the nasal structure (olfactory epithelium) or a neuro inflammation/degeneration in the superior olfactory pathway. The understanding of the origin of the smell alteration would be desirable for appropriate management of the problem. Unfortunately, clinical investigations do not always allow to define the exact cause. AREAS COVERED This review discusses the treatments available and their mechanism of action based on the administration methods; in fact, just looking at the results obtained by the researcher using topic versus systemic treatment, might be possible to speculate about the peripheral or central origin of the olfactory disorder. EXPERT OPINION Because COVID-19 causes olfactory loss and several treatments (topical and systemic) have been tested in this disease, we have decided to use this model of acquired olfactory loss to discuss the different therapeutical option. The authors believe these treatments might be an option also for treating olfactory disease related to neurodegeneration.
-
10.
Mental Health amid COVID-19 Pandemic: Appropriate Coping Strategies.
Ayenigbara, IO
Psychiatria Danubina. 2022;(2):325-333
Abstract
COVID-19 is a global public health crisis, and is turning to be a major mental health problem. This review provides a broad overview of mental health situations during COVID-19 pandemic in Africa and globally, while some preventive methods to improve mental health conditions during the pandemic were provided. In the Africa context, various government authorities must ensure the provision and accessibility to mental health care services such as routine preventive information, mental health counseling and self help measures, and social supports such as palliatives, basic needs and special financial assistance to the public during the pandemic. Generally, coping strategies such as personal care-based measures (adequate nutrition, personal hygiene, adequate sleep and rest) activity-based measures (regular physical exercise, learning new tasks and engaging in novel adventures and mindfulness meditation) and behavioral-based measures (avoidance of psychoactive substances, taking breaks from COVID-19-related information, social connectedness and showing supports to others, setting achievable targets, help seeking measures and psychiatrist's visitations, adherence to all COVID-19 preventive measures and uptake of the COVID-19 vaccines) are all viable preventive methods against mental health conditions during the pandemic globally. It is recommended that researchers should conduct more studies on the impacts of COVID-19 on mental health status in Africa populations to ensure a valid basis for proper interventions during and post pandemic era. Also, African countries should seek supports and routine guidance from appropriate international health organizations to ensure an updated and frequent mental health care delivery to the public.
